infect
respiratori
syncyti
viru
rsv
major
caus
death
immunocompromis
patient
hematolog
malign
hm
without
hematopoiet
cell
transplant
hct
incid
infect
estim
hct
mortal
rate
lower
respiratori
tract
infect
lrti
reach
new
therapi
strategi
need
improv
outcom
rsv
lrti
immunocompromis
host
rsv
diagnosi
confirm
risk
stratif
hm
patient
critic
given
high
cost
therapi
aerosol
high
mortal
rate
prior
studi
identifi
lymphopenia
neutropenia
rsv
detect
lower
respiratori
sampl
import
risk
factor
mortal
recognit
individu
high
risk
advers
outcom
could
improv
prompt
deliveri
ribavirin
treatment
may
reduc
mortal
previous
develop
immunodefici
score
index
base
clinic
characterist
laboratori
paramet
standard
risk
stratif
practic
allogen
hct
recipi
rsv
upper
respiratori
tract
infect
urti
group
high
risk
advers
outcom
rsv
hypothes
among
hm
patient
without
hct
autolog
hct
recipi
recipi
would
highest
risk
mortal
hypothes
isol
rsv
respiratori
pathogen
lower
respiratori
tract
among
patient
underw
fiberopt
bronchoscopi
would
associ
higher
mortal
demonstr
parainfluenza
viral
also
sought
determin
whether
sever
immunodefici
hct
recipi
determin
immunodefici
score
index
isi
sever
immunodefici
sid
predict
mortal
rsv
lrti
conduct
retrospect
review
adult
type
leukemia
lymphoma
multipl
myeloma
hm
underw
year
age
older
rsv
infect
care
univers
texa
md
anderson
cancer
center
patient
identifi
infect
control
databas
viral
infect
collect
data
patient
demograph
underli
malign
immun
statu
diagnosi
antivir
therapi
thorac
imag
microbiolog
data
also
collect
data
outcom
includ
hospit
admiss
intens
care
unit
icu
admiss
mechan
ventil
mortal
day
studi
approv
institut
review
board
accord
helsinki
declar
world
medic
associ
waiver
inform
consent
grant
defin
rsv
lrti
microbiolog
confirm
rsv
nasal
wash
swab
bal
fluid
b
new
infiltr
cxr
chest
ct
within
day
microbiolog
confirm
microbiolog
confirm
perform
use
either
shell
vial
cultur
direct
immunofluoresc
antibodi
test
per
institut
practic
time
stratifi
rsv
lrti
possibl
proven
rsv
defin
possibl
rsv
lrti
rsv
detect
upper
respiratori
tract
new
pulmonari
infiltr
chest
imag
suggest
viral
etiolog
proven
rsv
lrti
patient
rsv
detect
lower
respiratori
tract
obtain
bal
new
pulmonari
infiltr
chest
imag
suggest
viral
etiolog
direct
immunofluoresc
antibodi
test
less
sensit
pcr
detect
possibl
patient
detect
rsv
bal
fluid
proven
rsv
lrti
therefor
patient
rsv
detect
bal
also
consid
possibl
rsv
lrti
bal
defin
organ
viru
bacteria
fungu
known
caus
pneumonia
human
defin
neutropenia
absolut
neutrophil
count
lymphopenia
absolut
lymphocyt
count
consid
patient
receiv
ribavirin
therapi
prior
diagnosi
lrti
receiv
ribavirin
urti
stage
patient
receiv
ribavirin
therapi
time
diagnosi
lrti
receiv
ribavirin
lrti
stage
radiograph
imag
independ
review
two
pulmonologist
ev
discrep
resolv
mutual
agreement
exclud
patient
resolv
infiltr
known
prior
lrti
clinic
volum
overload
assess
echocardiographi
right
heart
catheter
respons
diuret
prior
patient
imag
avail
independ
review
case
radiologist
interpret
document
medic
record
use
bronchoscopi
perform
dedic
endoscopi
suit
supervis
experienc
result
bronchial
wash
exclud
minim
contamin
upper
respiratori
tract
patient
possibl
rsv
lrti
undergo
bronchoscopi
n
reason
perform
bronchoscopi
record
avail
tabl
hct
recipi
score
use
isi
sid
criteria
time
rsv
lrti
isi
rang
isi
score
calcul
previous
describ
point
given
anc
alc
point
age
year
point
given
myeloabl
condit
regimen
diseas
corticosteroid
within
day
rsv
infect
recent
hct
recipi
stratifi
isi
moder
risk
isi
isi
strata
sid
criteria
classifi
hct
recipi
three
strata
moder
immunodefici
mid
sever
immunodefici
sid
sever
immunodefici
vsid
mid
defin
hct
month
prior
lrti
leukocyt
count
alc
sid
defin
hct
month
prior
lrti
deplet
month
prior
lrti
deplet
month
prior
lrti
diseas
grade
leukocyt
count
alc
immunoglobulin
count
gl
vsid
defin
sid
risk
factor
present
time
lrti
descript
statist
calcul
demograph
clinic
therapeut
data
categor
variabl
compar
use
fisher
exact
test
continu
variabl
compar
use
analysi
varianc
multivari
logist
regress
analys
perform
identifi
independ
risk
factor
associ
mortal
patient
follow
entir
day
outcom
variabl
enter
multivari
model
backward
elimin
use
includ
variabl
p
final
model
univari
logist
regress
analys
perform
determin
whether
isi
sid
criteria
associ
mortal
surviv
curv
test
perform
compar
probabl
surviv
patient
differ
type
lrti
possibl
vs
proven
patient
differ
microbiolog
result
bal
bal
perform
growth
rsv
rsv
pathogen
patient
differ
immunodefici
risk
strata
midsidvsid
lowmoderatehigh
isi
statist
analys
perform
use
r
version
r
foundat
statist
comput
vienna
austria
test
signific
level
identifi
patient
met
inclus
exclus
criteria
underw
bronchoscopi
bal
tabl
median
age
year
rang
year
femal
patient
without
hct
possibl
rsv
lrti
diagnos
patient
proven
rsv
lrti
patient
recipi
younger
recipi
like
multipl
myeloma
underli
malign
corticosteroid
among
hct
recipi
median
time
hct
lrti
day
interquartil
rang
day
patient
without
hct
like
receiv
chemotherapi
within
month
rsv
lrti
neutropenia
lymphopenia
less
like
receiv
ribavirin
therapi
rsv
alon
detect
bal
sampl
rsv
concurr
respiratori
pathogen
detect
pathogen
alon
detect
pathogen
detect
major
patient
undergo
bronchoscopi
refer
procedur
discret
primari
oncologist
transplant
physician
tabl
hospit
time
rsv
common
among
patient
cohort
although
patient
without
hct
less
like
hospit
tabl
differ
rate
icu
admiss
mechan
ventil
mortal
mortal
patient
without
hct
recipi
recipi
mortal
high
across
group
patient
proven
lrti
like
admit
icu
vs
p
die
day
vs
p
day
vs
p
lrti
onset
tabl
univari
logist
regress
model
neutropenia
rsv
diagnosi
odd
ratio
confid
interv
ci
lymphopenia
rsv
diagnosi
ci
proven
lrti
ci
predict
mortal
tabl
lymphopenia
neutropenia
exhibit
high
degre
collinear
creat
two
multivari
model
model
includ
neutropenia
lymphopenia
candid
variabl
final
model
model
includ
lymphopenia
neutropenia
candid
variabl
final
model
model
adjust
neutropenia
proven
lrti
ribavirin
therapi
recipi
higher
risk
mortal
patient
without
hct
recipi
adjust
ci
p
neutropenia
adjust
ci
p
strongest
predictor
mortal
proven
lrti
remain
strong
predictor
mortal
adjust
adjust
ci
similarli
model
lymphopenia
adjust
ci
proven
lrti
adjust
ci
associ
higher
mortal
howev
associ
higher
mortal
model
ribavirin
therapi
remain
model
significantli
associ
lower
mortal
model
urti
stage
adjust
p
lrti
stage
adjust
ci
p
model
urti
stage
adjust
p
lrti
stage
adjust
ci
p
signific
differ
mortal
among
patient
rsv
lrti
first
half
mortal
second
half
studi
period
mortal
second
half
ci
p
surviv
curv
shown
patient
hm
hct
recipi
recipi
figur
signific
differ
surviv
group
p
curv
demonstr
patient
proven
lrti
lower
surviv
rate
possibl
lrti
p
figur
analys
reveal
signific
differ
surviv
curv
patient
undergo
bronchoscopi
neg
bal
pathogen
detect
bal
rsv
detect
bal
rsv
addit
pathogen
detect
bal
p
figur
patient
undergo
bronchoscopi
similar
surviv
neg
bal
pathogen
detect
bal
patient
rsv
addit
pathogen
detect
bal
fluid
lowest
surviv
though
like
due
small
sampl
size
signific
differ
patient
rsv
alon
detect
bal
fluid
p
figur
surviv
rate
significantli
differ
patient
start
ribavirin
therapi
urti
stage
infect
ribavirin
therapi
lrti
stage
infect
ribavirin
therapi
p
figur
calcul
isi
grade
sid
criteria
hct
recipi
measur
associ
mortal
individu
identifi
isi
higher
risk
mortal
individu
ci
p
tabl
similarli
individu
vsid
higher
risk
mortal
mid
ci
p
isi
grade
sid
criteria
predict
time
mortal
demonstr
surviv
curv
figur
analyz
isi
continu
variabl
increas
isi
increas
odd
mortal
ci
p
isi
predict
mortal
recipi
recipi
howev
analysi
subgroup
limit
sampl
size
ci
p
ci
p
agreement
isi
sid
criteria
modest
weight
cohen
kappa
coeffici
ci
observ
high
mortal
rsv
lrti
hm
patient
without
hct
howev
differ
mortal
hm
patient
without
hct
recipi
lymphopenia
neutropenia
independ
predictor
mortal
furthermor
detect
rsv
bal
fluid
defin
proven
rsv
lrti
associ
higher
mortal
day
higher
rate
icu
admiss
immunodefici
defin
isi
grade
sid
criteria
associ
higher
rate
mortal
consist
studi
viral
lrti
found
mortal
hm
patient
without
hct
high
mortal
rate
across
group
similar
studi
hm
patient
rsv
lrti
patient
acut
myeloid
leukemia
institut
patient
rsv
lrti
contemporari
cohort
hct
recipi
rsv
lrti
overal
mortal
rang
recipi
often
underli
malign
requir
immunosuppress
compar
howev
found
mortal
high
hm
patient
regardless
hct
statu
similar
group
found
differ
risk
mortal
recipi
seo
et
differ
risk
mortal
recipi
develop
lrti
rsv
parainfluenza
piv
influenza
rhinoviru
similarli
renaud
et
found
mix
cohort
patient
human
metapneumoviru
hmpv
lrti
rsv
lrti
overal
mortal
rsv
infect
high
signific
differ
mortal
recipi
though
hr
approach
statist
signific
hr
ci
p
found
higher
mortal
among
recipi
one
multivari
model
includ
neutropenia
lieu
lymphopenia
marker
immun
impair
result
reproduc
model
includ
lymphopenia
furthermor
found
differ
surviv
assess
analys
logist
regress
possibl
recipi
higher
risk
death
adjust
presenc
neutropenia
studi
definit
prove
previou
studi
show
associ
higher
risk
death
hct
recipi
rsv
lrti
separ
multivari
model
found
lymphopenia
neutropenia
associ
mortal
lymphopenia
associ
increas
progress
urti
marker
similarli
neutropenia
independ
associ
progress
rsv
convers
normal
lymphocyt
count
associ
low
rate
progress
furthermor
found
immunodefici
defin
isi
sid
criteria
mortal
whether
use
isi
sid
criteria
immunodefici
associ
mortal
around
rsv
lrti
similar
prior
studi
initi
develop
cohort
isi
consist
recipi
rsv
lrti
mortal
high
among
receiv
ribavirin
urti
stage
progress
lrti
day
among
present
lrti
receiv
ribavirin
diagnosi
day
importantli
isi
develop
cohort
recipi
design
predict
progress
rsv
urti
lrti
current
studi
show
isi
less
use
recipi
particularli
sinc
certain
criteria
diseas
may
applic
similarli
studi
patient
rsv
lrti
found
patient
identifi
isi
mortal
high
isi
also
associ
high
mortal
influenza
sid
criteria
first
studi
patient
rsv
infect
risk
factor
mortal
includ
lrti
statu
vsid
rsv
diagnosi
recent
studi
sid
criteria
patient
rsv
piv
hmpv
infect
show
mortal
patient
vsid
death
patient
mid
sid
find
consist
prior
studi
show
immunocompromis
patient
high
risk
mortal
rsv
agreement
find
associ
corticosteroid
use
time
lrti
mortal
corticosteroid
use
use
part
immunodefici
score
index
tool
predict
risk
progress
rsv
urti
lrti
recipi
independ
associ
progress
rsv
howev
mix
cohort
patient
hmpv
rsv
lrti
corticosteroid
use
hypoxemia
associ
increas
similarli
corticosteroid
use
diagnosi
rsv
infect
associ
higher
incid
hypoxemia
futur
prospect
studi
necessari
investig
time
dosag
corticosteroid
administr
relationship
mortal
rsv
lrti
hm
patient
rsv
infect
particularli
hct
recipi
consid
candid
ribavirin
therapi
urti
stage
earli
treatment
may
prevent
find
signific
differ
mortal
patient
start
ribavirin
therapi
given
lrti
stage
studi
design
investig
efficaci
ribavirin
furthermor
ribavirin
given
lrti
stage
still
benefici
instanc
demonstr
despit
lack
statist
signific
trend
toward
protect
effect
ribavirin
mortal
cohort
given
urti
stage
patient
eventu
develop
rsv
lrti
futur
prospect
studi
necessari
valid
optim
rout
oral
aerosol
time
urti
lrti
ribavirin
therapi
group
defin
patient
lrti
rsv
detect
upper
respiratori
tract
lower
respiratori
tract
symptom
new
pulmonari
howev
found
detect
rsv
bal
predict
wors
outcom
suggest
subset
patient
rsv
detect
bal
ie
proven
lrti
distinguish
without
ie
possibl
lrti
may
repres
distinct
group
higher
mortal
prompt
aggress
manag
may
desir
similar
find
waghmar
et
found
patient
rsv
detect
bal
fluid
higher
mortal
rate
greater
requir
supplement
oxygen
addit
hct
recipi
piv
detect
bal
fluid
higher
mortal
piv
detect
nasal
wash
alon
vs
high
mortal
rate
also
demonstr
immunocompromis
patient
hm
without
hct
detect
human
metapneumoviru
hct
recipi
day
human
rhinoviru
day
hct
recipi
human
coronaviru
day
hct
recipi
day
hm
patient
without
hct
bal
fluid
sever
limit
find
retrospect
cohort
analysi
find
requir
confirm
prospect
studi
patient
refer
bronchoscopi
possibl
rsv
lrti
may
less
sick
result
referr
bia
howev
patient
refer
sick
undergo
bronchoscopi
would
bia
result
toward
null
hypothesi
use
viral
cultur
direct
immunofluoresc
antibodi
test
detect
rsv
respiratori
viral
pathogen
institut
practic
time
caution
necessari
extrapol
find
patient
respiratori
virus
detect
use
polymeras
chain
reaction
assay
though
patient
rsv
isol
bal
fluid
consid
possibl
rsv
lrti
surviv
analys
suggest
meaning
differ
surviv
patient
bal
support
consolid
two
group
patient
also
possibl
includ
patient
rsv
infect
volum
overload
etiolog
pulmonari
infiltr
misclassif
patient
would
like
bia
result
toward
null
hypothesi
patient
volum
overload
classifi
possibl
lrti
associ
isi
mortal
recipi
interpret
caution
sinc
isi
develop
quantifi
immunodefici
recipi
small
size
cohort
small
number
death
n
could
measur
interact
proven
rsv
lrti
immunodefici
score
find
need
replic
larger
prospect
cohort
conclus
found
mortal
high
hm
patient
without
hct
develop
rsv
lrti
neutropenia
lymphopenia
predict
mortal
addit
isi
vsid
rsv
diagnosi
associ
higher
mortal
furthermor
detect
rsv
bal
fluid
associ
higher
mortal
without
rsv
detect
bal
routin
calcul
immunodefici
score
may
improv
risk
stratif
hct
recipi
data
bal
may
complement
immunodefici
use
identifi
patient
rsv
infect
respiratori
virus
greatest
risk
death
patient
would
ideal
candid
earli
ribavirin
therapi
clinic
trial
new
investig
drug
rfc
receiv
research
grant
gilead
consultingadvisori
board
honoraria
ablynx
janssen
adma
biolog
author
report
potenti
conflict
interest
ev
saf
dp
yz
lb
eah
rfc
contribut
research
design
ev
rfc
contribut
write
paper
ev
saf
jk
ja
ab
rfc
contribut
conduct
studi
ev
dp
yz
rfc
contribut
data
analysi
